Protalix BioTherapeutics
Protalix BioTherapeutics' revenue fell 1.2% to $53 million in fiscal 2025. Its operating margin was −10.4%, down from 7.3% a year earlier. Free cash flow was −$14 million, against $7 million a year earlier. The diluted share count fell 3.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Protalix BioTherapeutics does
Protalix is a biopharmaceutical company that makes treatments for rare diseases. It uses its own system, called ProCellEx, which grows proteins in plant cells in industrial-scale tanks. It says it was the first company to get FDA approval for a protein made this way.
It has two commercial products, both enzyme replacement therapies, which supply an enzyme that patients lack. Elelyso treats Gaucher disease. It has been approved in the United States since 2012, and Protalix has licensed the rights to sell it worldwide, other than in Brazil, to Pfizer under an agreement that runs until 2030. Elfabrio treats Fabry disease, and Protalix has two licensing and supply agreements with Chiesi, which is solely responsible for selling Elfabrio worldwide. Protalix also supplies the drug substance to Chiesi and Pfizer.
It is also developing new candidates. PRX-115 is a gout treatment in a Phase 2 trial. PRX-119 is a long-acting form of an enzyme called DNase I for diseases involving neutrophil extracellular traps. It is turning its focus toward early-stage treatments for rare diseases, including kidney diseases.
Its biggest risks, as it describes them
- It depends heavily on revenue from sales of Elfabrio and Elelyso.
- Its partners Chiesi and Pfizer control how its products are sold, and it must supply them with drug substance.
- Insurers may not cover or reimburse its products in every territory.
- Its products could cause serious side effects, or safety issues could emerge after approval.
- It has a limited commercial operating history.
Income statement
From fiscal 2023 to 2024, earnings per share fell 55.6% a year and net income 65.1% a year, while the share count fell by 2%. Protalix BioTherapeutics then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 39 | 17 | 24 | 20 | 15 |
| Debt incl. finance leases | — | 28 | — | — | — |
| Net debt (negative means net cash) | — | 11 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −6.0x | −5.9x | 3.8x | 2.6x | — |
| Current ratio | 1.9x | 1.4x | 1.5x | 2.3x | 2.5x |
| Quick ratio | 1.3x | 0.9x | 1.1x | 1.5x | 1.5x |
Cash flow
Projections
Project Protalix BioTherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Protalix BioTherapeutics says to expect
- Full year 2026: total revenues
Management expects to meet or exceed 2026 guidance for total revenues of approximately $78.0 million to $83.0 million
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $101,360 of Protalix BioTherapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | Dror BashanPresident and CEO, Director | Bought | 56,000 | $1.81 | $101,360 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 33.7% | −4.6% | −27.1% |
| Altman Z'' | −11.31 | −11.86 | −11.01 |
| Accruals ratio | 13.7% | −7.3% | 6.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Protalix BioTherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Protalix BioTherapeutics | FY25 | −1.2% | −10.4% | −25.8% | — | — | — | |
| Invivyd | FY25 | 110.5% | −104.0% | −109.1% | — | — | — | Compare |
| Q32 Bio | FY25 | — | 31.4% | −62.4% | — | −2.8x | 3 | Compare |
| Gossamer Bio | FY25 | −57.7% | −352.2% | −353.5% | — | — | 0 | Compare |
| Champions Oncology | FY26 | 4.4% | −1.9% | −8.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 9 | 21 | 34 | 55 | 63 | 38 | 48 | 66 | 53 | 53 |
| Revenue growth | 110.8% | 129.1% | 62.4% | 59.7% | 15.0% | −39.0% | 24.2% | 37.5% | −18.5% | −1.2% |
| Gross profit | 1 | 4 | 25 | 44 | 52 | 22 | 28 | 42 | 29 | 26 |
| Research and development | 30 | 32 | 33 | 45 | 38 | 30 | 29 | 17 | 13 | 20 |
| Operating income | −33 | −34 | −19 | −11 | 3 | −20 | −13 | 10 | 4 | −6 |
| Net income | −29 | −83 | −26 | −18 | −6 | −28 | −15 | 8 | 3 | −7 |
| Diluted EPS (US$) | −2.90 | −6.37 | −1.80 | −1.23 | −0.22 | −0.62 | −0.31 | 0.09 | 0.04 | −0.08 |
| Diluted shares (millions) | 10 | 13 | 15 | 15 | 29 | 44 | 48 | 82 | 81 | 78 |
| Cash flow | ||||||||||
| Cash from operations | −32 | −10 | −8 | −19 | −26 | −10 | −25 | −1 | 9 | −12 |
| Capital expenditure | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 |
| Free cash flow | −33 | −11 | −8 | −20 | −27 | −12 | −26 | −2 | 7 | −14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 0 | 0 | 1 | 3 | 2 | 2 | 3 | 3 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 63 | 51 | 38 | 18 | 18 | 39 | 17 | 24 | 20 | 15 |
| Debt incl. finance leases | 73 | 52 | — | 55 | — | — | 28 | — | — | — |
| Total assets | 82 | 72 | 61 | 45 | 68 | 74 | 56 | 84 | 73 | 82 |
| Total liabilities | 92 | 102 | 114 | 116 | 95 | 80 | 66 | 51 | 30 | 34 |
| Shareholders' equity | −10 | −30 | −53 | −70 | −27 | −6 | −11 | 34 | 43 | 48 |
| Margins and ratios | ||||||||||
| Gross margin | 8.7% | 19.0% | 72.8% | 80.1% | 82.7% | 57.4% | 58.9% | 64.9% | 54.5% | 48.8% |
| Operating margin | −360.5% | −163.8% | −56.4% | −19.6% | 4.3% | −53.4% | −27.3% | 16.0% | 7.3% | −10.4% |
| Net margin | −319.2% | −395.9% | −77.3% | −33.4% | −10.4% | −71.9% | −31.3% | 12.7% | 5.5% | −12.5% |
| Free cash flow margin | −358.2% | −52.0% | −24.6% | −36.5% | −42.5% | −30.6% | −53.8% | −3.8% | 13.8% | −25.8% |
| Rule of 40 (growth + FCF margin) | −247.4% | 77.1% | 37.8% | 23.2% | −27.5% | −69.7% | −29.6% | 33.7% | −4.6% | −27.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — | — | 72.5% | 7.6% | −14.4% |
| Return on assets | −32.7% | −108.0% | −39.7% | −34.3% | −11.5% | −39.0% | −23.1% | 11.9% | 3.7% | −8.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |